The yellow fever 17D virus as a platform for new live attenuated vaccines

• Published in: Human vaccines & immunotherapeutics Vol. 10; no. 5; pp. 1256 - 1265
• Main Authors: Bonaldo, Myrna C, Sequeira, Patrícia C, Galler, Ricardo
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2014
• Subjects: Animals; Humans; Review; Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - genetics; Vaccines, Attenuated - immunology; Yellow Fever - genetics; Yellow Fever - immunology; Yellow Fever - prevention & control; Yellow Fever 17D virus-vaccines-immune responses-expression vector-insertion sites-live recombinant; Yellow Fever Vaccine - administration & dosage; Yellow Fever Vaccine - genetics; Yellow Fever Vaccine - immunology; Yellow fever virus - genetics; Yellow fever virus - immunology; Yellow Fever 17D virus-vaccines-immune responses-expression vector-insertion sites-live recombinant
• ISSN: 2164-5515; 2164-554X
• DOI: 10.4161/hv.28117

The live-attenuated yellow fever 17D virus is one of the most outstanding human vaccines ever developed. It induces efficacious immune responses at a low production cost with a well-established manufacture process. These advantages make the YF17D virus attractive as a vector for the development of new vaccines. At the beginning of vector development studies, YF17D was genetically manipulated to express other flavivirus prM and E proteins, components of the viral envelope. While these 17D recombinants are based on the substitution of equivalent YF17D genes, other antigens from unrelated pathogens have also been successfully expressed and delivered by recombinant YF17D viruses employing alternative strategies for genetic manipulation of the YF17D genome. Herein, we discuss these strategies in terms of possibilities of single epitope or larger sequence expression and the main properties of these replication-competent viral platforms.